Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

For the full year 2025, Solventum forecasts organic sales growth of 1.0% to 2.0% and adjusted EPS of $5.45 to $5.65. The midpoint of the EPS guidance range is slightly above the current analyst ...

The Maplewood, Minnesota-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, were $1.41 per share. The results topped Wall Street expectations.

Reports Q4 revenue $2.074B, consensus $2.05B. “Solventum (SOLV) executed another quarter of solid performance, enabling us to deliver full year ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Thermo Fisher Scientific Inc. (Waltham, Mass.) announced that the company has entered into a definitive agreement with Solventum  to acquire Solventum’s ...

Thermo Fisher Scientific is buying Solventum’s purification & filtration unit for $4.1 billion in cash, strengthening its ...

Nvidia said sales, driven by the chips that power artificial intelligence, rose 78% to $39.3 billion in its latest quarter. Net income rose 80% to $22 billion. Both figures came in ahead of Wall ...

Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

There’s still a dearth of mega deals. The largest deal from the past week was Sun Communities (Latham & Watkins advising) ...